ADC Therapeutics SA represents a strong commitment to advancing the field of oncology by developing targeted antibody-drug conjugates (ADCs) for the treatment of various types of cancer. The company's corporate philosophy centers around innovation, scientific rigor, and patient-centricity. With a focus on ADC technology, ADC Therapeutics aims to provide effective and precise treatments that improve patients' quality of life. By harnessing the power of ADCs, the company strives to address the unmet medical needs of cancer patients and contribute to the advancement of personalized cancer therapy. ADC Therapeutics SA's dedication to cutting-edge research and development underscores its mission to revolutionize cancer treatment options.

ADC Therapeutics SA is primarily present in multiple regions and countries across the globe. These include the United States, Europe, and Asia. The company has its headquarters in Lausanne, Switzerland, but operates globally to expand its reach and deliver its innovative therapies. With a focus on the development and commercialization of antibody drug conjugates (ADCs), ADC Therapeutics SA has established a presence in key pharmaceutical markets worldwide. This allows them to collaborate with healthcare professionals and deliver their targeted therapies to address unmet medical needs.

ADC Therapeutics SA has achieved several significant milestones since its inception. The company successfully completed its initial public offering (IPO) in May 2020, raising a total of $267 million. In October 2020, ADC Therapeutics SA received accelerated approval from the U.S. Food and Drug Administration (FDA) for Loncastuximab tesirine (ZYNLONTA™), a groundbreaking antibody-drug conjugate for the treatment of relapsed or refractory large B-cell lymphoma. This approval marked a major milestone for the company and demonstrated the potential of its innovative platform technology. These achievements highlight ADC Therapeutics SA's commitment to developing novel therapies and its dedication to improving the lives of patients.

ADC Therapeutics SA is a Swiss-based biotechnology company specializing in the development of targeted antibody-drug conjugates (ADCs) for the treatment of cancer. Founded in 2012, ADC Therapeutics SA has been dedicated to addressing unmet medical needs through the innovative combination of monoclonal antibodies with potent cytotoxic agents. The company's extensive research capabilities and expertise have led to the development of a robust pipeline of ADC candidates, targeting various solid tumors and hematological malignancies. ADC Therapeutics SA is committed to advancing the field of oncology and improving patient outcomes through the development of novel ADC therapies.

The main competitors of ADC Therapeutics SA in the market include other leading companies in the field of antibody-drug conjugates (ADCs) and the broader oncology drug market. Some notable competitors include Seattle Genetics Inc., Immunomedics Inc., and ImmunoGen Inc. These companies are also focused on developing and commercializing innovative ADC therapies for the treatment of various types of cancer. ADC Therapeutics SA strives to differentiate itself by leveraging its proprietary Pyrrolobenzodiazepine (PBD) technology platform, which offers distinct advantages in terms of enhanced potency and tumor-targeted drug delivery.

ADC Therapeutics SA is primarily active in the biotechnology industry.

ADC Therapeutics SA is a biotechnology company focused on the development of antibody drug conjugates (ADCs) for the treatment of cancer. Their business model revolves around using their proprietary technology platform to develop targeted therapies that combine monoclonal antibodies with highly potent cytotoxic agents. By precisely delivering these cytotoxic agents to cancer cells, ADC Therapeutics aims to improve treatment outcomes while minimizing side effects. With a growing pipeline and collaborations with pharmaceutical partners, ADC Therapeutics SA is dedicated to advancing the field of ADCs and providing innovative solutions to patients with unmet medical needs.

The ADC Therapeutics P/E ratio is -1.04.

The ADC Therapeutics P/S ratio is 1.96.

The Quality Investing for ADC Therapeutics is 2/10.

The expected ADC Therapeutics revenue is 82.87 M USD.

The expected ADC Therapeutics profit is -156.67 M USD.

ADC Therapeutics SA is a biopharmaceutical company specializing in the development and commercialization of antibody-drug conjugates (ADCs) for the treatment of cancer. ADC Therapeutics believes that ADCs have the potential to significantly improve the efficacy and safety of cancer treatments.

ADC Therapeutics pays a dividend of 0 USD distributed over payouts per year.

The dividend cannot currently be calculated for ADC Therapeutics or the company does not pay out a dividend.

The ISIN of ADC Therapeutics is CH0499880968.

The WKN of ADC Therapeutics is A2PSR8.

The ticker of ADC Therapeutics is ADCT.

Over the past 12 months, ADC Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, ADC Therapeutics is expected to pay a dividend of 0 USD.

The current dividend yield of ADC Therapeutics is .

ADC Therapeutics pays a quarterly dividend. This is distributed in the months of .

ADC Therapeutics paid dividends every year for the past 0 years.

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

ADC Therapeutics is assigned to the 'Health' sector.

To receive the latest dividend of ADC Therapeutics from 1/1/2025 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 1/1/2025.

The last dividend was paid out on 1/1/2025.

In the year 2024, ADC Therapeutics distributed 0 USD as dividends.

The dividends of ADC Therapeutics are distributed in USD.